Terns Pharmaceuticals
TERN
Performance
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a portfolio of small-molecule therapeutics to address serious diseases, with an emphasis on oncology and metabolic conditions such as obesity. The company conducts its research and development activities to advance drug candidates through clinical trials with the aim of delivering targeted cancer therapies and metabolic disease treatments. While the site highlights its headquarters and leadership, it emphasizes a global outlook in oncology and metabolic programs.
Recent News
Merck Completes $5.3 B Purchase of Terns, Adding Oral CML Drug TERN‑701
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Marker Therapeutics Inc (MRKR) Q1 2026 Earnings Call Transcript
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Top Biotech Deals in March 2026
FDA Grants Breakthrough Therapy Designation to TERN-701 for Relapsed Ph+ CML
#58894
Merck Still Sees ‘Compelling’ Outlook for Terns Leukemia Drug
Top 20 Most Innovative Healthcare Companies in 2026, Per Fast Company
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
Oil Prices Fall Even With Ceasefire Plan Uncertainty
Merck Eyes $6 Billion in Seven-Part Bond Sale for Terns Deal
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer
Regulatory Actions for April 28, 2026
Recent Deals
Terns Pharmaceuticals Secures Full Licensing Rights for Leukemia Drug TERN-701 From Hansoh Pharmaceutical
Merck Subsidiary Thailand Merger Sub Launches $53 per Share Tender Offer for Terns Pharmaceuticals
MSD Completes $5.3B Acquisition of Terns Pharmaceuticals
Merck to Acquire Terns Pharmaceuticals for $6.7B